Eli Lilly's shares rose nearly 6% following the European Medicines Agency's CHMP recommendation to approve Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all therapy lines. This approval would allow use regardless of prior treatment with BTK inhibitors, broadening patient access in the EU. The recommendation is based on positive Phase 3 trial data and now awaits final approval from the European Commission, expected within one to two months. Lilly has also submitted data to the US FDA, with a decision anticipated in late 2026.
GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are driving high demand among employees, but their high costs are causing many large employers to reduce or reconsider coverage. Although oral pills are as expensive as injectables and less effe...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, for treating adults with chronic lymphocytic leukemia (CLL) across all lin...
ProQR Therapeutics has priced a $50 million underwritten registered direct offering of 27.6 million shares at $1.81 each, alongside a concurrent private placement of 5.1 million shares to Eli Lilly for $9.2 million. The funds will support ProQR's RNA...
Eli Lilly has finalized its acquisition of Centessa Pharmaceuticals, a company developing orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders. This acquisition strengthens Lilly's neuroscience portfolio, aiming to address severe ...
President Trump highlighted the creation of over 2,600 manufacturing jobs in Pennsylvania during a visit to the Mack Trucks facility. He credited his administration's policies, including rolling back stringent fuel emissions regulations, for boosting...
